CHPF

Across TCGA pan-cancer cohorts, CHPF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHPF data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CHPF mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CHPF expression acts as an unfavorable survival marker.

PDAC, LSCC, and GBM are the cancer types where CHPF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.149	0.915	.010	37	view →
LSCC	DFS	Tertile	II,III,IV	0.621	0.902	.005	22	view →
GBM	DFS	Quartile	All	0.184	0.439	.001	14	view →
CCRCC	DFS	Median	II,III,IV	0.379	1.000	.020	12	view →
LUAD	OS	Median	All	0.773	0.906	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CHPF–PDAC (OS)

Open the PDAC breakdown →